Epigenetic Therapies for Cancer | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Loss-of-function mutations in TET2 occur frequently in patients with clonal hematopoiesis,
myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) and are associated …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

Oxoglutarate-dependent dioxygenases (2OGDDs) are a superfamily of enzymes that play
diverse roles in many biological processes, including regulation of hypoxia-inducible factor …

Background The molecular determinants of clinical responses to decitabine therapy in
patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are …

Recent genetic analyses of large populations have revealed that somatic mutations in
hematopoietic cells leading to clonal expansion are commonly acquired during human …

Myelodysplastic syndrome (MDS) is a clonal disease that arises from the expansion of
mutated haematopoietic stem cells. In a spectrum of myeloid disorders ranging from clonal …

The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and
personalized variety of therapeutic approaches. Among them, allogeneic hematopoietic …